Background: Clostridium difficile infections pose significant risks to patients in the post-acute care setting, including prolonged hospitalization and increased mortality. In 2015 and 2016, the facility noted an increase of healthcare acquired Clostridium difficile cases on its long term acute care (LTAC) and skilled nursing (SNF) units. The purpose of this study was to determine whether implementing Saccaromyces boulardii, a daily probiotic supplement, for patients who were receiving intravenous (IV) antibiotics would reduce the rate of healthcare acquired Clostridium difficile cases.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Infection Control
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect